|
|
|
|
||
Re: Mizuho is cautiousOncology is not a field that HZNP has thus far ventured into, and it is not easily integrated into their existing sales force. Don't think they want to take on that much additional staff until existing revenue streams mature. They have dipped their toe into oncology with Actimmune combo trials, but they are all funded by other companies or the ACA. Not a direction that I think HZNP is going in any time soon, but ultimately something for their M&A brain trust to assess. |
return to message board, top of board |